These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 28631135)

  • 41. Erlotinib in advanced non-small cell lung cancer: efficacy and safety findings of the global phase IV Tarceva Lung Cancer Survival Treatment study.
    Reck M; van Zandwijk N; Gridelli C; Baliko Z; Rischin D; Allan S; Krzakowski M; Heigener D
    J Thorac Oncol; 2010 Oct; 5(10):1616-22. PubMed ID: 20736854
    [TBL] [Abstract][Full Text] [Related]  

  • 42. EGFR-Co-Mutated Advanced NSCLC and Response to EGFR Tyrosine Kinase Inhibitors.
    Barnet MB; O'Toole S; Horvath LG; Selinger C; Yu B; Ng CC; Boyer M; Cooper WA; Kao S
    J Thorac Oncol; 2017 Mar; 12(3):585-590. PubMed ID: 27639677
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Phase 1/2 study of rilotumumab (AMG 102), a hepatocyte growth factor inhibitor, and erlotinib in patients with advanced non-small cell lung cancer.
    Tarhini AA; Rafique I; Floros T; Tran P; Gooding WE; Villaruz LC; Burns TF; Friedland DM; Petro DP; Farooqui M; Gomez-Garcia J; Gaither-Davis A; Dacic S; Argiris A; Socinski MA; Stabile LP; Siegfried JM
    Cancer; 2017 Aug; 123(15):2936-2944. PubMed ID: 28472537
    [TBL] [Abstract][Full Text] [Related]  

  • 44. EGFR and KRAS Mutations in ALK-Positive Lung Adenocarcinomas: Biological and Clinical Effect.
    Sahnane N; Frattini M; Bernasconi B; Zappa F; Schiavone G; Wannesson L; Antonelli P; Balzarini P; Sessa F; Mazzucchelli L; Tibiletti MG; Martin V
    Clin Lung Cancer; 2016 Jan; 17(1):56-61. PubMed ID: 26381283
    [TBL] [Abstract][Full Text] [Related]  

  • 45. First-line gefitinib treatment for patients with advanced non-small cell lung cancer with poor performance status.
    Lee YJ; Kim HT; Han JY; Yun T; Lee GK; Kim HY; Sung JH; Lee JS
    J Thorac Oncol; 2010 Mar; 5(3):361-8. PubMed ID: 20107420
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer.
    Brugger W; Triller N; Blasinska-Morawiec M; Curescu S; Sakalauskas R; Manikhas GM; Mazieres J; Whittom R; Ward C; Mayne K; Trunzer K; Cappuzzo F
    J Clin Oncol; 2011 Nov; 29(31):4113-20. PubMed ID: 21969500
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study.
    Cappuzzo F; Ciuleanu T; Stelmakh L; Cicenas S; Szczésna A; Juhász E; Esteban E; Molinier O; Brugger W; Melezínek I; Klingelschmitt G; Klughammer B; Giaccone G;
    Lancet Oncol; 2010 Jun; 11(6):521-9. PubMed ID: 20493771
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The epidermal growth factor receptor-tyrosine kinase inhibitor era has changed the causes of death of patients with advanced non-small-cell lung cancer.
    Wu WS; Chen YM; Tsai CM; Shih JF; Lee YC; Perng RP; Whang-Peng J
    J Chin Med Assoc; 2013 Dec; 76(12):682-5. PubMed ID: 24064329
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prospective cohort study of clinical characteristics and management patterns for patients with non-small-cell lung cancer in the Russian Federation: EPICLIN-Lung.
    Tjulandin S; Imyanitov E; Moiseyenko V; Ponomarenko D; Gurina L; Koroleva I; Karaseva V
    Curr Med Res Opin; 2015 Jun; 31(6):1117-27. PubMed ID: 25867537
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib.
    Eberhard DA; Johnson BE; Amler LC; Goddard AD; Heldens SL; Herbst RS; Ince WL; Jänne PA; Januario T; Johnson DH; Klein P; Miller VA; Ostland MA; Ramies DA; Sebisanovic D; Stinson JA; Zhang YR; Seshagiri S; Hillan KJ
    J Clin Oncol; 2005 Sep; 23(25):5900-9. PubMed ID: 16043828
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The role of smoking status on the progression-free survival of non-small cell lung cancer patients harboring activating epidermal growth factor receptor (EGFR) mutations receiving first-line EGFR tyrosine kinase inhibitor versus platinum doublet chemotherapy: a meta-analysis of prospective randomized trials.
    Hasegawa Y; Ando M; Maemondo M; Yamamoto S; Isa S; Saka H; Kubo A; Kawaguchi T; Takada M; Rosell R; Kurata T; Ou SH
    Oncologist; 2015 Mar; 20(3):307-15. PubMed ID: 25657199
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Survival outcomes in patients with advanced non-small cell lung cancer treated with erlotinib: expanded access programme data from Belgium (the TRUST study).
    Van Meerbeeck J; Galdermans D; Bustin F; De Vos L; Lechat I; Abraham I
    Eur J Cancer Care (Engl); 2014 May; 23(3):370-9. PubMed ID: 24152297
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Phase II study of pemetrexed plus intermittent erlotinib combination therapy for pretreated advanced non-squamous non-small cell lung cancer with documentation of epidermal growth factor receptor mutation status.
    Minami S; Kijima T; Hamaguchi M; Nakatani T; Koba T; Takahashi R; Takeuchi Y; Kida H; Nagatomo I; Yamamoto S; Tachibana I; Komuta K; Kawase I
    Lung Cancer; 2013 Nov; 82(2):271-5. PubMed ID: 23993733
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Gene mutations in squamous cell NSCLC: insignificance of EGFR, KRAS and PIK3CA mutations in prediction of EGFR-TKI treatment efficacy.
    Fiala O; Pesek M; Finek J; Benesova L; Bortlicek Z; Minarik M
    Anticancer Res; 2013 Apr; 33(4):1705-11. PubMed ID: 23564819
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Erlotinib in routine clinical practice for first-line maintenance therapy in patients with advanced non-small cell lung cancer (NSCLC).
    Faehling M; Achenbach J; Staib P; Steffen U; Tessen HW; Gaillard VE; Brugger W
    J Cancer Res Clin Oncol; 2018 Jul; 144(7):1375-1383. PubMed ID: 29687154
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Everolimus and erlotinib as second- or third-line therapy in patients with advanced non-small-cell lung cancer.
    Papadimitrakopoulou VA; Soria JC; Jappe A; Jehl V; Klimovsky J; Johnson BE
    J Thorac Oncol; 2012 Oct; 7(10):1594-601. PubMed ID: 22968184
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Imaging Characteristics of Driver Mutations in EGFR, KRAS, and ALK among Treatment-Naïve Patients with Advanced Lung Adenocarcinoma.
    Park J; Kobayashi Y; Urayama KY; Yamaura H; Yatabe Y; Hida T
    PLoS One; 2016; 11(8):e0161081. PubMed ID: 27518729
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Detection of EML4-ALK fusion genes in non-small cell lung cancer patients with clinical features associated with EGFR mutations.
    Shaozhang Z; Xiaomei L; Aiping Z; Jianbo H; Xiangqun S; Qitao Y
    Genes Chromosomes Cancer; 2012 Oct; 51(10):925-32. PubMed ID: 22736493
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Abnormalities of epidermal growth factor receptor in lung squamous-cell carcinomas, adenosquamous carcinomas, and large-cell carcinomas: tyrosine kinase domain mutations are not rare in tumors with an adenocarcinoma component.
    Ohtsuka K; Ohnishi H; Fujiwara M; Kishino T; Matsushima S; Furuyashiki G; Takei H; Koshiishi Y; Goya T; Watanabe T
    Cancer; 2007 Feb; 109(4):741-50. PubMed ID: 17238183
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Expression Profiling of Driver Genes in Female Never-smokers With Non-adenocarcinoma Non-small-cell Lung Cancer in China.
    Zhao Y; Dong Y; Zhao R; Zhang B; Wang S; Zhang L; Hu M; He Q; Zhang W; Han B
    Clin Lung Cancer; 2020 Sep; 21(5):e355-e362. PubMed ID: 32139332
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.